# Celularity

Source: https://onco.cc/companies/celularity/  
OnCo record `celularity` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Celularity makes cell therapies and other products from the placenta after birth. It developed a ready-made natural killer cell therapy that was tested in acute myeloid leukaemia and glioblastoma, but the company now describes its main focus as diseases of ageing rather than cancer.

## Summary

Celularity, listed on Nasdaq as CELU and based in Florham Park, New Jersey, develops placenta-derived cell therapies and biomaterials. Its own timeline traces it to Anthrogenesis, founded in 1998, which merged with Celgene in 2002; Celularity was spun out in 2017 and became a public company in 2021. Its NK cell platform page describes CYNK-001 as a cryopreserved, allogeneic, off-the-shelf natural killer cell therapy and lists clinical programmes in newly diagnosed acute myeloid leukaemia (NCT04310592) and glioblastoma (NCT04489420), as well as multiple myeloma and COVID-19. The current pipeline page leads with unmodified placental mesenchymal-like cells for Crohn's disease, diabetic foot ulcers and facioscapulohumeral muscular dystrophy, and lists an early-stage engineered T cell programme for solid tumours. The company describes its targets as age-related diseases.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: Celularity Inc
- HQ: Florham Park, NJ
- Type: cell-therapy
- Website: https://celularity.com/
- Ticker: CELU

## Notes

- Founded is the 2017 spin-out year on the company's timeline; its predecessor Anthrogenesis dates from 1998. The status and results of the CYNK-001 trials were not checked, and those trials are not yet records in OnCo. The solid tumour T cell programme has no named indication or phase on the pipeline page. HQ is the business address in SEC EDGAR.

## Sources

- Official website: https://celularity.com/
- About and timeline: https://celularity.com/about/
- NK cell platform: https://celularity.com/nk-cell-platform/
- Pipeline: https://celularity.com/pipeline/
- SEC filings: https://celularity.com/sec-filings/

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [NK cell therapy and CAR-NK](https://onco.cc/technologies/nk-cell-therapy/)

---
JSON: https://onco.cc/api/v1/entities/celularity.json